• MeSH
• Blood Transfusion, Autologous * statistics & numerical data   MeSH
• Cytapheresis statistics & numerical data   MeSH
• Hemodilution statistics & numerical data   MeSH
• Blood microbiology   MeSH
• Humans MeSH
• Plasmapheresis statistics & numerical data   MeSH
• Preoperative Care * MeSH
• Surveys and Questionnaires MeSH
• Blood Component Removal statistics & numerical data   MeSH
• Statistics as Topic MeSH
• Health Facilities MeSH
• Check Tag
• Humans MeSH
• Publication type
• Statistics MeSH
• News MeSH
• Geographicals
• Czech Republic MeSH

Peripheral blood stem cells (PBSCs) are preferred source of hematopoietic stem cells for autologous transplantation. Mobilization of PBSCs using chemotherapy and/or granulocyte colony-stimulating factor (G-CSF) however fails in around 20%. Combining G-CSF with plerixafor increases the mobilizations success. We compared cost-effectiveness of following schemes: the use of plerixafor "on demand" (POD) during the first mobilization in all patients with inadequate response, the remobilization with plerixafor following failure of the first standard mobilization (SSP), and the standard (re)mobilization scheme without plerixafor (SSNP). Decision tree models populated with data from a first-of-a-kind patient registry in six Czech centers (n = 93) were built to compare clinical benefits and direct costs from the payer's perspective. The success rates and costs for POD, SSP and SSNP mobilizations were; 94.9%, $7,197; 94.7%, $8,049; 84.7%, $5,991, respectively. The direct cost per successfully treated patient was $7,586, $8,501, and $7,077, respectively. The cost of re-mobilization of a poor mobilizer was $5,808 with G-CSF only and $16,755 if plerixafor was added. The total cost of plerixafor "on-demand" in the sub-cohort of poor mobilizers was $17,120. Generally, plerixafor improves the mobilization success by 10% and allows an additional patient to be successfully mobilized for incremental $11,803. Plerixafor is better and cheaper if used "on demand" than within a subsequent remobilization.

• MeSH
• Cost-Benefit Analysis MeSH
• Cytapheresis statistics & numerical data   MeSH
• Length of Stay statistics & numerical data   MeSH
• Child MeSH
• Adult MeSH
• Models, Economic MeSH
• Granulocyte Colony-Stimulating Factor economics   therapeutic use   MeSH
• Heterocyclic Compounds economics   therapeutic use   MeSH
• Infant MeSH
• Middle Aged MeSH
• Humans MeSH
• Lymphoma economics   surgery   MeSH
• Adolescent MeSH
• Young Adult MeSH
• Multiple Myeloma economics   surgery   MeSH
• Hematopoietic Stem Cell Mobilization economics   methods   MeSH
• Child, Preschool MeSH
• Decision Trees MeSH
• Aged MeSH
• Peripheral Blood Stem Cell Transplantation economics   MeSH
• Health Expenditures MeSH
• Treatment Outcome MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Infant MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Male MeSH
• Child, Preschool MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Multicenter Study MeSH
• Research Support, Non-U.S. Gov't MeSH
• Comparative Study MeSH
• Geographicals
• Czechoslovakia MeSH

• MeSH
• Blood Transfusion, Autologous * methods   statistics & numerical data   MeSH
• Cytapheresis statistics & numerical data   MeSH
• Hemodilution statistics & numerical data   MeSH
• Plasmapheresis statistics & numerical data   MeSH
• Preoperative Care MeSH
• Surveys and Questionnaires MeSH
• Health Facilities * MeSH
• Publication type
• Statistics MeSH
• Tables MeSH
• Geographicals
• Czech Republic MeSH